Financial guidance 2020
MorphoSys increased its financial guidance for the financial year 2020.
in € million |
Guidance 2020 |
Results 2019 |
---|---|---|
Group Revenues | 317 to 327 | 71.8 |
R&D expenses | 130 to 140 | 108.4 |
Group EBIT | 10 to 20 | - 107.9 |
This updated guidance reflects higher revenues from partnerships and collaborations and Tremfya® royalties are expected to be at the upper end of guidance. In addition, it now also includes revenues from product sales of Monjuvi® (tafasitamab-cxix) following its approval and subsequent launch in the U.S. This updated guidance is based on constant currency exchange rates and does not include any effects from potential in-licensing or co-development deals for new development candidates. The operational and financial guidance might potentially be impacted by the ongoing global COVID-19 crisis on MorphoSys’ business operations including but not limited to the Company’s supply chain, clinical trial conduct, as well as timelines for regulatory and commercial execution.